Immune-Related Adverse Events for GI Toxicity - Colitis

ورودی‌های بالینی بیمار

حداقل ۰ — حداکثر ۲۰ • واحد: stools/day

پنل نتیجه و تصمیم بالینی
در انتظار ورودی‌ها
irae grade
—grade
آماده برای ارزیابی

پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.

طبقات خطر و بازه‌های امتیاز:
  • —1–1
  • —2–2
  • —3–3
  • —4–4
Direct Clinical Answer

The Immune-Related Adverse Events for GI Toxicity - Colitis calculates staging malignant disease, estimating overall survival, and assessing chemotherapy tolerability. Key inputs include stool increase per day. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.

Clinical Guidelines & Evidence

Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations

Clinical Indication

The Immune-Related Adverse Events for GI Toxicity - Colitis is indicated for bedside clinical practice to support Grades severity of colitis secondary to immune checkpoint inhibitor therapy and provides management recommendations. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.

Target Population

Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.

Limitations & Contraindications

Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care. Clinical exclusion: Stool studies should exclude infectious causes (C. diff, CMV, parasites).

Clinical Pearls & Action Plan

Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Most frequently occurs 5-10 weeks after ICPi treatment initiation.

Formula & Variables:

Grading based on stool frequency increase over baseline, presence of incontinence, functional impact, and hospitalization needs: Grade 1 (<4 stools/day increase), Grade 2 (4-6 stools/day increase), Grade 3 (≥7 stools/day increase, incontinence, limiting self-care), Grade 4 (life-threatening consequences)

Input Parameters

NameTypeRequiredDescription
stool_increase_per_dayintegerYesIncrease in number of stools per day over baseline(stools/day)
incontinence_presentstringYesPresence of fecal incontinence
functional_impactstringYesImpact on activities of daily living and self-care
hospitalization_indicatedstringYesClinical indication for hospitalization

Score Interpretation & Guidance

RangeStageDescription
1–1—Mild - Increase of <4 stools per day over baseline
2–2—Moderate - Increase of 4-6 stools per day over baseline
3–3—Severe - Increase of ≥7 stools per day, incontinence, limiting self-care
4–4—Life-threatening - Life-threatening consequences, urgent intervention required

Evidence-Based References (EBM)

  • Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385.DOI: 10.1200/JCO.2017.77.6385
  • Thompson JA, Schneider BJ, Brahmer J, Andrews S, Armand P, Bhatia S, et al. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020. J Natl Compr Canc Netw. 2020 Mar 1;18(3):230-241. doi: 10.6004/jnccn.2020.0012.DOI: 10.6004/jnccn.2020.0012
  • Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.DOI: 10.1001/jamaoncol.2018.3923
  • Gupta A, De Felice KM, Loftus EV Jr, Khanna S. Systematic review: colitis associated with anti-CTLA-4 therapy. Aliment Pharmacol Ther. 2015 Aug;42(4):406-17. doi: 10.1111/apt.13281.DOI: 10.1111/apt.13281

Related calculators